In pediatric patients who have growth hormone deficiency (GHD), treatment with somatropin stimulates linear growthand normalizes concentrations of Insulin-like Growth Factor -I (IGF-I).In adults with GHD, treatment with somatropin results in reduced fat mass, increased lean body mass, metabolic alterations that include beneficial changes in lipid metabolism, and normalization of IGF-I concentrations
The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomised, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly, CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomised, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2)
The HA-based nanogel stably adhered to the wound surface, promoting re-epithelialization while effectively limiting the pathological activation of fibroblasts by inhibiting YAP nuclear translocation and TEAD complex formation
Storage (after first puncture): 28C, used within 28 days
Preclinical timelines run over weeks meaningful model-level changes appear across roughly weeks 412, not in the first days
